Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors
Upon spinal cord injury, axons attempting to regenerate need to overcome the repulsive actions of myelin-associated inhibitors, including the myelin-associated glycoprotein, Nogo-A, and the oligodendrocyte myelin glycoprotein. These inhibitors bind and signal through a neuronal receptor/co-receptor/transducer complex composed of NgR1, Lingo-1, and p75. Consequently, p75 is cleaved by alpha secretase followed by gamma-secretase, triggering downstream signaling that inhibits axonal regrowth. ADAM10 and ADAM17 are both known to function as alpha secretases in neurons. Here we show that ADAM17, and not ADAM10, is the alpha secretase that recognizes and cleaves p75, when it is a part of a 5-component neuron-myelin signaling complex comprising NgR1, Lingo-1, p75, GT1b, and a myelin inhibitor. Importantly, we demonstrate the ability of inhibitory anti-ADAM17 mAbs to abrogate the cleavage of p75 in a neuroblastoma-glioma cell line and reverse the neurite outgrowth inhibition by myelin-associated inhibitors.
Authors
- Yevgeniy Romin (ORCID: https://orcid.org/0000-0003-3649-6813)
- Eric Chan (ORCID: https://orcid.org/0009-0002-2835-3994)
- Rachelle Mendoza (ORCID: https://orcid.org/0000-0001-6087-2335)
- Murray J. Tipping (ORCID: https://orcid.org/0000-0001-5262-2723)
- Dimitar B. Nikolov (ORCID: https://orcid.org/0000-0001-8774-5061)
- Nayanendu Saha (ORCID: https://orcid.org/0000-0001-8371-9819)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University Irving Medical Center (US)
- New York Proton Center (US)
Publication Details
- Journal
- Life Science Alliance
- Published
- 2025-03-25
- DOI
- https://doi.org/10.26508/lsa.202403126
- Citations
- 1
- Primary Topic
- Nerve injury and regeneration
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health